Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News on Pharma

1 Stock That’ll Make You Turn Blue in the Face for Owning

Biotech company bluebird bio (BLUE) received FDA approval for ZYNTEGLO last month, which seems to have boosted its stock price. However, given its bleak profitability and stretched valuations, the stock might be best avoided. Read on….

StockNews.com

America's fentanyl problem a growing threat for teens

America's epidemic of drug overdoses tied to fentanyl is a growing threat for teens, particularly as the pills are increasingly disguised, officials warn.

Axios

Important Biotech Catalysts For September 15, 2022 - End Of The Day Summary

Pfizer (NYSE:PFE) announced positive top-line results from the pivotal Phase 3 trial assessing the safety, tolerability, and immunogenicity of its investigational pentavalent meningococcal vaccine (MenABCWY) in healthy individuals 10 through 25 years of age. The trial met all primary and secondary endpoints. Pfizer shares traded in a range of $45.7…

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

2 Reliable Drug Stocks to Buy and Hold for Big-Time Gains

Persistent rate hikes by the Fed and rising odds of a recession have aggravated market turbulence and led investors to seek refuge in defensive sectors such as healthcare. Defensive stocks tend to perform well in declining markets due to the steady demand for their products. Hence, consistent dividend-yielding drug stocks…

StockNews.com

US warns monkeypox could mutate to resist antiviral drug

U.S. health officials are warning doctors against overusing the lone drug available to treat monkeypox

The Independent UK

Pharma services company's shares go up by 12% after it confirms insider dealing probe

Dublin-listed Open Orphan confirmed it is helping gardai in respect of the investigation

Irish Mirror

This 1 Stock Pays You Just for Owning It

Leading pharmaceutical company Pfizer (PFE) did exceptionally well during the pandemic thanks to the high demand for its COVID-19 vaccine, and it still has enough growth prospects. The company’s focus on strengthening its pipeline via business acquisitions, product development, and approvals is expected to deliver impressive growth in the upcoming…

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

Payment of ₹200 crore to drug companies for supply of Remdesivir in Karnataka stuck due to breach of tender condition

More than a year after the drug was supplied, payments to major pharma companies are stalled due to this violation.

The Hindu

Important Biotech Catalysts For September 14, 2022 - End Of The Day Summary

The U.S. Food and Drug Administration (FDA) has granted fast track designation for the development of TRACON’s (NASDAQ:TCON) lead asset envafolimab (KN035) for patients with locally advanced, unresectable or metastatic undifferentiated pleomorphic sarcoma (UPS) and myxofibrosarcoma (MFS) who have progressed on one or two prior lines of chemotherapy. TRACON shares…

Benzinga

The Worst Biotech Stock to Own in September

Biotech stock Ginkgo Bioworks (DNA) has fallen more than 60% year-to-date. The company has been making some acquisitions recently to aid its growth over the next few years. However, given its weak financials and unfavorable analyst estimates, it may not be wise to invest in this stock now. Continue reading….

StockNews.com

New ALS drug funded by Ice Bucket Challenge already in use in South Florida trials

While the country awaits federal approval of a new ALS drug, people in South Florida with the disease already are using it.

Tribune News Service

Is the new omicron vaccine worth it?

The omicron-specific booster vaccine hit the market — some wonder if it's worth getting

Salon

Commentary: Did the US jump the gun with the new omicron-targeted vaccines?

Last month, the FDA authorized omicron-specific vaccines, accompanied by breathless science-by-press release and a media blitz. Just days after the FDA’s move, the Centers for Disease Control and Prevention followed, recommending updated boosters for anyone age 12 and up who had received at least two doses of the original COVID-19…

Tribune News Service

Ban drug ads to promote health

Advertising promoting new drugs is effective but often leads to inappropriate prescribing. To protect the health of their citizens, countries should ban it.

360info

Get all your
news in one place.

100's of premium titles.
One news app.

WEKU

A Minnesota man has been sentenced to life in prison for 11 fentanyl deaths

Aaron Broussard was sentenced to life in prison for 11 deaths that were tied to controlled substances he sold. Those who died thought they were taking Adderall, but they actually ingested fentanyl.

Reuters

Dozen of child deaths prompt Gambia to suspend paracetamol syrup sales

Gambia on Tuesday ordered importers and shops to suspend sales of all brands of paracetamol syrup while the government investigates a suspected link between the medicine and the deaths of dozens of young children.

Liverpool Echo

Gene therapy firm growing its Liverpool footprint with new build

A three-storey lab site was approved earlier today

The Guardian - US

Canadian advocates pledge to continue selling pure drugs amid overdose crisis

Over the last six years, the vast majority of overdose deaths in British Columbia have been driven by impurities in street drugs

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Important Biotech Catalysts For September 12, 2022 - End Of The Day Summary

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Mersana Therapeutics’ (NASDAQ:MRSN) lead candidate XMT-1660 for the treatment of adult patients with advanced or metastatic triple-negative breast cancer (TNBC). Mersana shares traded as high as 1.79 percent, in a range of $7.48 to $7.94 on day…

StockNews.com

2 Biotech Stocks Defying the Bear Market and 1 That's Not

The biotech industry is poised to grow thanks to breakthrough developments and increasing demand from an aging population. Fundamental strength and inelastic demand have been helping biotech stocks Amgen Inc. (AMGN) and Gilead Sciences, Inc. (GILD) defy the bear market. However, Timber Pharmaceuticals, Inc. (TMBR) has been struggling to survive…

StockNews.com

3 Health Care Stock Under $50 You Can Buy Today

The healthcare industry is anticipated to grow significantly in the coming years, thanks to strong demand amid rising chronic diseases, technological advancements, and rising healthcare spending. Therefore, we think fundamentally sound healthcare companies Pfizer (PFE), GSK Plc (GSK), and Teva Pharmaceutical (TEVA), which are currently trading under $50, could be…

The Hindu

German firm DFE Pharma’s CoE opened in Genome Valley

‘Capabilities offered through this centre can reduce the time to launch a product’

The National (Scotland)

Cannabis-based medicine approved for use in Scotland for those living with MS

A CANNABIS-BASED medicine has been approved for use for people living with multiple sclerosis (MS) in Scotland.

Asharq Al-Awsat

EU Regulator Backs Pfizer's BA.4/5-Adapted COVID Booster

The European Medicines Agency (EMA) on Monday recommended a COVID-19 booster designed to combat Omicron offshoots BA.4/5, days after endorsing a pair of boosters tailored to target the older BA.1 variant. The latest recommendation is for a so-called bivalent vaccine developed by Pfizer and BioNTech, which targets BA.4/5 as well…

The Independent UK

EU regulator clears Pfizer-BioNTech's tweaked COVID booster

The European Medicines Agency has recommended the authorization of a tweaked booster dose of the Pfizer-BioNTech coronavirus vaccine that includes protection against two of the latest versions of omicron, as countries look to bolster their immunization programs ahead of winter

1 … 129 130 131 132

People

Joe Biden

67,926 stories

Dipanjan BanchurSince

722 stories

Mangeet Kaur BounsMangeet

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Centers for Disease Control and Prevention

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.